Medherant appoints new Chairman
Medherant has brought in Dr Ken Cunningham as Chair in a bid to strengthen the company as it moves into clinical trialling with its TEPI Patch technology. Dr Cunningham has worked for 25 year within the pharmaceutical industry, including performing the role of Chief Executive Office of SkyePharma during the years 2006 to 2010.
Medherant had recently announced the successful completion of £1.5 million in funding for its drug delivery system.
Ken Cunningham commented, “I am delighted to join Medherant as Chairman as the team progresses the Company’s TEPI Patch technology into clinical development. Medherant’s novel transdermal drug delivery patch technology offers significant benefits to patients and the potential to generate value for Medherant’s shareholders. I look forward to contributing to the success of the company.”
Peter Dines, Head of Life Sciences & Bio-sciences at Mercia, said, “Mercia previously worked with Ken when he chaired Polytherics, which later acquired the Mercia portfolio company Warwick Effect Polymers. He then took the business onto AIM as Abzena plc. We are delighted that he has now taken up this post. Ken has over two decades of experience in this sector and his appointment reflects the enormous potential offered by the TEPI Patch.”